AR050084A1 - Derivados de bencimidazolona como inhibidores de hsp90 - Google Patents
Derivados de bencimidazolona como inhibidores de hsp90Info
- Publication number
- AR050084A1 AR050084A1 ARP050103071A ARP050103071A AR050084A1 AR 050084 A1 AR050084 A1 AR 050084A1 AR P050103071 A ARP050103071 A AR P050103071A AR P050103071 A ARP050103071 A AR P050103071A AR 050084 A1 AR050084 A1 AR 050084A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- halogen
- amidino
- cyano
- substituted
- Prior art date
Links
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical class C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- -1 piperidino, morpholinyl Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere al uso de compuestos de benzoimidazolona y sales de los mismos, en el tratamiento de enfermedades proliferativas, y para la fabricacion de preparaciones farmacéuticas que comprenden compuestos de benzoimidazolona, a compuestos de benzoimidazolona y a un proceso para la preparacion de los compuestos de benzoimidazolona. Reivindicacion 4: Un compuesto de acuerdo con la formula (1) en donde: R1 es H, halogeno, alquilo inferior sustituido o insustituido; R2 es H, halogeno, alquilo inferior sustituido o insustituido, carboxilo, COR5, SO2R5, CX2R5, CXHR5, CH2R5, CHR5R6, CR5(R6)2, o C(R5)2R6; R3 es H, alquilo inferior sustituido o insustituido, halogeno, -SO2NH2, o formula 2, R4 es OH; R5 es alquilo inferior; -(CH2)n- NR62; -YR6; -Y(CH2)m-NR62; formulas 3, 4 o 5; n es 1 o 2, m es 2 o 3; X es halogeno; Y1 es alquileno, O, S o N; Y2 e Y3 son cada uno independientemente metileno, O o NR; R6 es H, alquilo inferior, cicloalquilo, heterociclilo, cicloalquilo fusionado, heterociclilo fusionado, o NR9 R10 forman juntos un anillo heterocíclico con el átomo de N; forman un anillo heterocíclico de 3 a 8 miembros que contiene de 1 a 4 átomos de nitrogeno, oxígeno o azufrre (por ejemplo azetidinilo, pirrolidinilo, piperidino, morfolinilo, imidazolinilo, piperazinilo, o alquilo inferior-piperazinilo); cicloalaquilo como se define anteriormente, en especial cicloalaquilo C3-6, alcanoílo inferior (de preferencia como un solo sustituyente de amino, o en combinacion con otra de las fracciones que no son acilo recién mencionadas), y benzoílo, o fenil-alcanoílo inferior (de preferencia como un solo sustituyente de amino, o en combinacion con otra de las fracciones que no son acilo recién mencionadas), ciano, ciano-alquilo inferior, tal como ciano-metilo, amidino, N-hidroxi-amidino, amidino-alquilo inferior, tal como -metilo o N-hidroxi-amidino-alquilo inferior, tal como -metilo; R7 es alquilo inferior, halogeno, alcoxilo inferior, o -Y1-(CH2)p -N(R8) (H); p es de 1 a 3; R8 es H o alquilo inferior, o sales farmacéuticasmente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59133004P | 2004-07-27 | 2004-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050084A1 true AR050084A1 (es) | 2006-09-27 |
Family
ID=35058768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103071A AR050084A1 (es) | 2004-07-27 | 2005-07-25 | Derivados de bencimidazolona como inhibidores de hsp90 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090069341A1 (es) |
| EP (1) | EP1776110A1 (es) |
| JP (1) | JP2008508217A (es) |
| KR (1) | KR20070045290A (es) |
| CN (1) | CN101027054A (es) |
| AR (1) | AR050084A1 (es) |
| AU (1) | AU2005266493B2 (es) |
| BR (1) | BRPI0513857A (es) |
| CA (1) | CA2574139A1 (es) |
| MX (1) | MX2007001131A (es) |
| PE (1) | PE20060572A1 (es) |
| RU (1) | RU2007106933A (es) |
| TW (1) | TW200612922A (es) |
| WO (1) | WO2006010594A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1704856A4 (en) * | 2003-12-26 | 2009-08-19 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITOR OF THE HSP90 FAMILY |
| TW200718689A (en) * | 2005-04-14 | 2007-05-16 | Chiron Corp | 2-Amino-quinazolin-5-ones |
| JP2009504673A (ja) * | 2005-08-11 | 2009-02-05 | ノバルティス アクチエンゲゼルシャフト | ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および１７−ａａｇのようなｈｓｐ９０阻害剤を含む組合せ |
| DE602006021205D1 (de) | 2005-10-07 | 2011-05-19 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| WO2007092496A2 (en) * | 2006-02-07 | 2007-08-16 | Conforma Therapeutics Corporation | 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors |
| WO2008024963A1 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
| FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| JP5311673B2 (ja) | 2006-12-14 | 2013-10-09 | エグゼリクシス， インコーポレイテッド | Ｍｅｋ阻害剤の使用方法 |
| CN101663302B (zh) * | 2007-04-18 | 2013-07-24 | 橘生药品工业株式会社 | 含氮稠环衍生物、包含所述含氮稠环衍生物的药物组合物及其医药用途 |
| CN101821247A (zh) | 2007-10-12 | 2010-09-01 | 艾科尔公司 | 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物 |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| CN102786512A (zh) * | 2012-05-31 | 2012-11-21 | 中国人民解放军军事医学科学院毒物药物研究所 | N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ239540A (en) * | 1990-09-24 | 1993-11-25 | Neurosearch As | 1-phenyl benzimidazole derivatives and medicaments |
| US5621007A (en) * | 1993-11-03 | 1997-04-15 | Bristol-Myers Squibb Company | Method for regulation of transmembrane chloride conductance |
| US7211561B2 (en) * | 2001-10-12 | 2007-05-01 | Cedars-Sinai Medical Center | Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa) |
| JP2007505142A (ja) * | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
-
2005
- 2005-07-25 PE PE2005000865A patent/PE20060572A1/es not_active Application Discontinuation
- 2005-07-25 AR ARP050103071A patent/AR050084A1/es not_active Application Discontinuation
- 2005-07-26 AU AU2005266493A patent/AU2005266493B2/en not_active Ceased
- 2005-07-26 CN CNA2005800323187A patent/CN101027054A/zh active Pending
- 2005-07-26 MX MX2007001131A patent/MX2007001131A/es active IP Right Grant
- 2005-07-26 US US11/658,365 patent/US20090069341A1/en not_active Abandoned
- 2005-07-26 TW TW094125263A patent/TW200612922A/zh unknown
- 2005-07-26 JP JP2007523003A patent/JP2008508217A/ja not_active Withdrawn
- 2005-07-26 EP EP05775880A patent/EP1776110A1/en not_active Withdrawn
- 2005-07-26 BR BRPI0513857-4A patent/BRPI0513857A/pt not_active IP Right Cessation
- 2005-07-26 WO PCT/EP2005/008118 patent/WO2006010594A1/en not_active Ceased
- 2005-07-26 CA CA002574139A patent/CA2574139A1/en not_active Abandoned
- 2005-07-26 RU RU2007106933/04A patent/RU2007106933A/ru unknown
- 2005-07-26 KR KR1020077004505A patent/KR20070045290A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1776110A1 (en) | 2007-04-25 |
| JP2008508217A (ja) | 2008-03-21 |
| CN101027054A (zh) | 2007-08-29 |
| CA2574139A1 (en) | 2006-02-02 |
| WO2006010594A1 (en) | 2006-02-02 |
| AU2005266493B2 (en) | 2009-09-10 |
| KR20070045290A (ko) | 2007-05-02 |
| TW200612922A (en) | 2006-05-01 |
| MX2007001131A (es) | 2007-03-15 |
| AU2005266493A1 (en) | 2006-02-02 |
| RU2007106933A (ru) | 2008-09-10 |
| US20090069341A1 (en) | 2009-03-12 |
| BRPI0513857A (pt) | 2008-05-20 |
| PE20060572A1 (es) | 2006-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050084A1 (es) | Derivados de bencimidazolona como inhibidores de hsp90 | |
| DE60322359D1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
| AR015176A1 (es) | Derivados pirazol y derivados de pirazol condensados que incluyen indazoles, su procedimiento de preparacion, preparado farmaceutico y su utilizacionpara la preparacion de medicamentos. | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| AR037731A1 (es) | Uso de ureas de benzotiazoles | |
| HUP0402352A2 (hu) | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| CL2003002756A1 (es) | Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia. | |
| AR057769A1 (es) | Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR086528A2 (es) | Combinacion farmaceutica | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| AR064619A1 (es) | Derivados de amino-imidazopiridinas, composiciones farmaceuticas que los contienen y usos de los mismos como agentes antitumorales. | |
| PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
| ECSP045368A (es) | "antagonistas de los receptores de trombina" | |
| AR045762A1 (es) | Derivados de quinazolina | |
| DE60140456D1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| AR035068A1 (es) | Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos | |
| AR051461A1 (es) | Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla | |
| DE602004012758D1 (de) | Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung | |
| AR037418A1 (es) | Derivados de benzotiazol | |
| AR031526A1 (es) | Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento. | |
| AR042148A1 (es) | Derivados de indazol como antagonistas de crf | |
| AR034249A1 (es) | Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |